TCG Crossover Management, LLC
CIK: 0001839948Latest portfolio: $3.0B · Q4 2025
Holdings
43
Total Value
$3.0B
New Positions
8
Closed Positions
5
Top Holdings
View All 43 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ABVXABIVAX SA AMERICAN DEPOSITARY SHARES | 7,111,596 | $959.0M | 31.74% | — | |
| 2 | COGTCOGENT BIOSCIENCES INC | 5,868,162 | $208.4M | 6.90% | -930,000 | |
| 3 | CGONCG ONCOLOGY INC | 3,670,206 | $152.4M | 5.04% | — | |
| 4 | TNGXTANGO THERAPEUTICS INC | 12,762,094 | $113.1M | 3.74% | +4.2M | |
| 5 | CNTACENTESSA PHARMACEUTICALS PLC | 4,286,480 | $107.2M | 3.55% | +1.1M | |
| 6 | DYNDYNE THERAPEUTICS INC | 4,615,144 | $90.3M | 2.99% | — | |
| 7 | RAPTRAPT THERAPEUTICS INC | 2,582,408 | $87.5M | 2.89% | +946K | |
| 8 | TYRATYRA BIOSCIENCES INC | 2,898,103 | $76.2M | 2.52% | — | |
| 9 | AMLXAMYLYX PHARMACEUTICALS INC | 6,243,812 | $75.4M | 2.50% | — | |
| 10 | YB4PSAVARA INC | 12,362,205 | $74.5M | 2.47% | — | |
| 11 | GLUEMONTE ROSA THERAPEUTICS INC | 4,622,151 | $72.5M | 2.40% | NEW | |
| 12 | OCULOCULAR THERAPEUTIX INC | 5,740,231 | $69.7M | 2.31% | -377,001 | |
| 13 | DNTHDIANTHUS THERAPEUTICS INC | 1,676,624 | $69.1M | 2.29% | — | |
| 14 | EYPTEYEPOINT PHARMACEUTICALS INC | 3,572,335 | $65.3M | 2.16% | — | |
| 15 | GPCRSTRUCTURE THERAPEUTICS INC | 920,857 | $64.0M | 2.12% | -142,143 | |
| 16 | SYRESPYRE THERAPEUTICS INC | 1,900,582 | $62.3M | 2.06% | +800K | |
| 17 | FULCFULCRUM THERAPEUTICS INC | 5,250,000 | $59.4M | 1.97% | — | |
| 18 | LQDALIQUIDIA TECHNOLOGIES INC | 1,710,084 | $59.0M | 1.95% | — | |
| 19 | BHVNBIOHAVEN LTD | 4,631,317 | $52.3M | 1.73% | NEW | |
| 20 | IMVTIMMUNOVANT INC | 1,660,933 | $42.2M | 1.40% | NEW | |
| 21 | KODKODIAK SCIENCES INC | 1,445,538 | $40.4M | 1.34% | +300K | |
| 22 | ADCTADC THERAPEUTICS SA | 11,390,175 | $40.2M | 1.33% | +10.0M | |
| 23 | LBRXLB PHARMACEUTICALS INC | 1,745,015 | $38.8M | 1.29% | -1 | |
| 24 | XNCRXENCOR INC | 2,452,138 | $37.5M | 1.24% | — | |
| 25 | RVMDREVOLUTION MEDICINES INC | 436,473 | $34.8M | 1.15% | — |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare0.0% ($9.590342084371523e+197T)
Unknown0.0% ($74.5M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $3.0B | 43 |
| Q3 2025 | Nov 17, 2025 | $2.0T | 40 |
| Q2 2025 | Aug 14, 2025 | $875.5B | 38 |
| Q1 2025 | May 14, 2025 | $733.1B | 38 |
| Q4 2024 | Feb 14, 2025 | $1.0T | 38 |
| Q3 2024 | Nov 14, 2024 | $1180.3T | 36 |
| Q2 2024 | Aug 14, 2024 | $959.5T | 32 |
| Q1 2024 | May 15, 2024 | $1264.9T | 33 |
| Q4 2023 | Feb 14, 2024 | $901.7T | 29 |
| Q3 2023 | Nov 14, 2023 | $679.1T | 26 |
| Q2 2023 | Aug 14, 2023 | $609.8T | 22 |
| Q1 2023 | May 15, 2023 | $513.0T | 22 |
| Q4 2022 | Feb 14, 2023 | $566.6T | 21 |
| Q3 2022 | Nov 14, 2022 | $333.4B | 21 |
| Q2 2022 | Aug 15, 2022 | $235.4B | 22 |
| Q1 2022 | May 16, 2022 | $249.1B | 20 |
| Q4 2021 | Feb 18, 2022 | $213.6B | 15 |
Fund Information
TCG Crossover Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $3.0B across 43 holdings. The largest position is ABIVAX SA AMERICAN DEPOSITARY SHARES (ABVX), representing 31.7% of the portfolio. Compared to the previous quarter, the fund opened 8 new positions and closed 5 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.